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ABSTRACT: Methods for making specific modifications to the genomes of living cells are powerful research tools. Two 
methods currently dominate, CRISPR and Cre recombinase. CRISPR has the advantage that it can act on unmodified target 
genes; Cre has the advantage of being available in drug-inducible versions, allowing temporal control, but it requires engi-
neering (‘floxing’) of the target gene. Here, we have combined these advantages by constructing drug (tamoxifen / mife-
pristone)-inducible Cas9 and Cpf1 CRISPR effectors. We demonstrate their low background activity and robust activation 
with drugs, by using gRNAs to target them to TetR, in a cell carrying a Tet-repressed reporter gene. As well as being useful 
in their own right, the research tools generated here will pave the way to making further drug-controlled effector proteins. 
Synthetic biology provides potentially useful technolo-
gies for materials synthesis, for sensing, and for construc-
tion of tissues, and provides new tools and perspectives for 
the study of basic biology.  Among the most useful syn-
thetic tools built so far for mammalian systems are induci-
ble transcriptional switches that exert temporal and dose-
dependent control over gene expression.  
 
Engineered systems can be controlled through chemical, 
biological, and electromagnetic methods. The chemical 
option often involves the use of small molecules, which has 
several advantages: it offers a quick start, it is reversible, it 
can operate deep inside tissues that are inaccessible to 
light and, unlike biological agents such as viruses, most of 
the chemicals involved are too small to be immunogenic so 
they can be re-used indefinitely.  
  
Figure 1. a) The T-REx system is a Tetracycline-Regulated Expression System for Mammalian Cells. In the absence of tetracycline, 
the Tet repressor binds to the TetO2, repressing the transcription of the transgene. Upon addition, tetracycline binds to the Tet 
repressor rendering it unable to bind to the Tet operator. As a result, the gene of interest is transcribed. b) Cas9 and Cpf1 are 
components of the Class II CRISPR systems. They present three main differences: the PAM sequence, the type of cut and the 
number of gRNAs. c) In this paper, we engineer ligand-binding domains of nuclear hormone receptors without loss of function in 
Cas9 or Cpf1 to create the inducible CRISPR systems. 
 
 
One of the best-known chemically inducible system for 
control of mammalian gene expression is probably the Tet 
on/off system, developed over 25 years ago from compo-
nents of the bacterial Tn10-encoded Tet operon (1). Cur-
rently there are two broad classes of Tet-based gene regu-
lation, one activates gene expression in the presence of tet-
racycline/ doxycycline and the other represses it. Ther-
mofisher’s T-REx system is based on the binding of the Tet 
repressor protein to a Tet operator-containing promoter 
that controls the gene of interest. This binding is inhibited 
by tetracycline/ doxycycline so, when these chemicals are 
present, so the promoter is not repressed, and the gene is 
activated (Figure 1a). Other systems use a fusion protein 
made from the Tet repressor and a viral transcriptional ac-
tivator, which will activate transcription from a basal pro-
moter with a Tet operator site unless tetracycline/doxycy-
cline is present, when binding is blocked and the gene is 
off. The main advantages of the Tet system are its rapidity 
and reversibility. Although the system was invented some 
time ago, the number of studies using this system remains 
high (https://www.ncbi.nlm.nih.gov/pub-
med/?term=Tet+inducible). 
 
Other small molecule inducible systems, such as the ra-
pamycin or the nuclear hormone receptor systems, are 
available (2). Nuclear hormone receptors exhibit a modular 
structure, having different physical protein domains that 
correspond closely to functional domains: these can be in-
terchanged between related receptors without loss of func-
tion. Among them, the ERT2 is a truncated form of the es-
trogen steroid receptor that has the advantage of providing 
orthogonality because it binds to the steroid antagonist 4-
Hydroxytamoxifen but not to the endogenous hormone es-
trogen.  For example, 4-Hydroxytamoxifen has been com-
bined with site-specific recombinases systems such the 
Cre-loxP to create the Cre-ERT2 system which has the 
speed advantage of regulating the Cre recombinase at the 
protein level (3). The ERT2 motif has also been fused to ex-
pression constructs of transcription factors involved in 
neurogenesis (i.e., ASCL1 and NEUROD1) for temporal 
control of virus-mediated gene expression in adult mouse 
Neural stem/progenitor cells. (4). A Zscan4c–ERT2 fusion 
protein has also been used to demonstrate an active role of 
Zscan4 in increasing the ability of mouse embryonic stem 
cells to contribute to a whole embryo (5).  
  
Figure 2. Schematic of our system. Diagram of the system representing the tight control of mCherry expression by combining 
the TetR system and the inducible CRISPR system. The reversible action: In the presence of tetracycline or doxycycline, the TetR 
does not bind the tetO allowing the reporter to be expressed. Afterwards, by removing the tetracycline, the reporter expression 
can be again inhibited. The irreversible action:  When a drug (4-hydroxytamoxifen or mifepristone) is added to the inducible 
CRISPR system, the CRISPR is transported to the nucleus where it disrupts its target gene, the TetR. With no more TetR being 
transcribed once the gene has been deleted, the inhibition exerted by the TetR system is not functional anymore and the re-
porter is permanently expressed. 
 
 
 
Recent developments have created a tool that is even 
more popular than the TetR system (6). Also having a bac-
terial origin, in this case as a protective mechanism against 
exogenous DNA, the Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR) Type II system has 
been manipulated to be used in eukaryotic systems. The 
CRISPR system is currently the most commonly used RNA-
Guided Endonuclease technology for genome engineering. 
Among the class II CRISPR effectors, Cas9 and Cpf1 (Figure 
1b) have been remodelled for genome engineering (7) and, 
through deletion of nuclease domains and fusion with 
transcriptional activating or repressing domains, for RNA 
guided transcriptional regulation (8). They have also been 
modified for epigenetic regulation by fusing dCas9 to dif-
ferent epigenetic modifiers for targeted epigenetic modifi-
cation at specific loci in the genome (9), and for imaging of 
chromatin within live cells (10). 
 
The RNA-guided nature of Cas9 and Cpf1 brings some 
advantages over the operator-guided mechanism of Tet, 
because a gene of interest does not have to be placed arti-
ficially under the control of an operator-containing pro-
moter and natural genes can be targeted in the context of 
their natural promoters and chromatin. The Tet system, 
though, has the advantage of being switchable using a 
small molecule, allowing gene control to be exerted at a 
time of an experimenter’s choosing.  We believe that a 
range of tools that combine both of these features would 
be of interest for the research community. In this study we 
have therefore developed four small molecule-inducible 
CRISPR effectors for use in mammalian cells. We demon-
strate their use in a system that combines the TetR system 
with the inducible CRISPR system. First, the transgene ex-
pression of a reporter was placed under the reversible con-
trol of a Tet operator, so that the expression of the reporter 
occurs only in the presence of tetracycline/ doxycycline. 
Next, a drug-inducible irreversible ‘on’ system was created 
by disrupting the Tet repressor with either of two drug-in-
ducible CRISPR systems (HR-Cas9 and HR-Cpf1), each be-
ing made in varieties sensitive to one of two different 
drugs. 
 
RESULTS AND DISCUSSION 
Construction of the reporter system and verifica-
tion of gRNAs  
The system we have designed to demonstrate drug-con-
trolled CRISPR action depends on CRISPR-mediated dis-
ruption of the gene encoding a TetR transcription inhibi-
tor. In our test cells, this TetR inhibitor normally inhibits 
the expression of the mCherry fluorescent reporter gene 
(Figure 2). As a first step, we constructed a basic gene ex-
pression system in which mCherry was placed under the 
control of a CMV promoter to which the Tet operator site, 
TetO, had been added (Figure 3a, schematic). This was 
achieved by cloning the mCherry gene into the commercial 
expression vector, pcDNA4/TO, to create a pcDNA4/TO-
mCherry construct and transferring it into T-REx-293 cells,  
              
 
 
Figure 3. a) Tetracycline-regulated mCherry expression: The images show T-REx-293 cells stably expressing the TetR protein 
transfected with an inducible vector containing the reporter mCherry as gene of interest. After tetracycline addition, the tran-
scription of the mCherry is initiated. It can be repressed again by tetracycline removal. b) Irreversible expression of mCherry on 
T-REx-293 -TO- mCherry cells co-transfected with Cas9 and Cpf1. Two weeks after transfection are required for the complete 
reporter expression. (10x objective; Scale bars: 200 µm).
which already contain the TetR gene. After antibiotic se-
lection, stable clones were tested for tetracycline-con-
trolled mCherry expression. As expected, the cells did not 
express the reporter unless tetracycline was added to in-
hibit TetR (Figure 3a). When it was added they did express 
mCherry but ceased to do so on tetracycline removal. This 
confirmed an effective, reversible control of the mCherry 
reporter gene by TetR. 
Our next step was to test the ability of a constitutive 
CRISPR system to effectively disrupt the TetR gene. We co-
transfected cells of the T-REx- 293-TO-mCherry clone de-
scribed above with a plasmid encoding the CRISPR effec-
tors sp-Cas9, or hAsCpf1, and also with a plasmid encoding 
gRNA designed to target the effector to the TetR gene (Fig-
ure 3b schematic). Both CRISPR systems were able to dis-
rupt TetR inhibition of mCherry reporter expression (Fig-
ure 3b).  
The main drawback of our system was that gene editing 
was slow: It was not until 6 days post-transfection that the 
first evidence of mCherry expression was evident and 4 to 
6 extra days were needed for maximal mCherry appearance 
in the cultures. After tetracycline addition, the mCherry 
expression was observable within hours, showing that the 
delay was in gene editing and disappearance of the TetR 
mRNA and protein, and not in transcription and transla-
tion of mCherry itself. For many applications, particularly 
disease modelling in in vivo mammalian systems, delays of 
a few days will not be important (it takes many weeks for 
gene loss to result in a tumour, cyst etc anyway). If faster 
timing were important, it may be possible to have a 
method to destroy the target protein at the same time than 
the gene expression was downregulated. Perhaps, for ex-
ample, an auxin-inducible degron could be integrated in 
the system to completely degrade the target protein at the 
    
Figure 4. 4-Hydroxytamoxifen (4-OHT) inducible Cas9. a) Schematic representation of the wild type Cas9 and three successful 
fusion proteins of Cas9 with the ligand binding domain of a mutated form of the estrogen receptor ERT2. The gRNA targets the 
TetR in all four constructs. b) Percentage of T-REx-293-mCherry positive cells after (+ 4-OHT) or without (- 4-OHT) TetR disrup-
tion with the three 4-OHT inducible Cas9 comparing to the number of mCherry positive cells after TetR disruption by the wild 
type Cas9. c) Micrographs of the T-REx-293-mCherry cells after TetR disruption either with the Cas9 or each of the inducible Cas9 
(10x objective; Scale bars: 200 µm).    
 
same time than the gene is disrupted. This would, though, 
involve more work on modifying the genome and therefore 
abrogate the advantages of CRISPR over Cre.  
Creation of ERT2- Cas9 fusion proteins  
The need for inducible genome editing was appreciated 
soon after the generation of the first transgenic knockout 
mice (11). While some conventional knockouts were ade-
quate for studying the function of a gene when that gene 
had a highly restricted pattern of expression or function, in 
many cases devastating effects of loss of gene function at 
early stages of development made it impossible to assess 
the function of the gene at later stages. An example is pro-
vided by the tumour suppressor, WT1, loss of which is im-
plicated in the development of the human kidney nephro-
blastoma, Wilms’ tumour (12). Attempts to create a mouse 
model of Wilms’ tumour by making a homozygous knock-
out of the WT1 gene failed because, in the absence of the 
gene, no kidneys formed in the first place (13).  Dissecting 
the role of WT1 in repressing tumour formation depended 
on removing gene function only once kidneys had begun 
to develop, either by RNAi in culture (14) or by exploiting 
conditional knockout techniques in vivo.  The most com-
mon conditional knockout technique flanks the target 
gene of interest with loxP sites and places Cre recom-
binase, which recognizes and recombines these sites, un-
der the control of a cell-specific promoter (15). Further con-
trol on this system was added by Feil and colleagues, who 
made a fusion protein between Cre and ERT2 (16): this fu-
sion protein was only active in the presence of 4-Hydroxy-
tamoxifen, allowing control of Cre activity in time and 
space (17). 
The Cre-ERT2 system works well but it involves exten-
sive genetic modification because the target gene must be 
flanked by LoxP sites (‘floxed’): it is therefore not a tech-
nique amenable to high-throughput studies of gene loss. 
CRISPR gene editing targets genes in their natural state, 
requiring only a gRNA for guidance, so can be applied to 
wild-type genomes and is suited to high-throughput stud-
ies, CRISPR being in all tests and only the gRNA changing 
between them. Conventional CRISPR does not, however, 
allow drug-mediated timed activation.  
To confer control by 4-Hydroxytamoxifen on CRISPR ac-
tivity, we engineered several designs of fusion protein be-
tween Cas9 and the ligand binding domain of a mutated 
form of the estrogen receptor (ERT2) that binds to steroid 
antagonist 4-Hydroxytamoxifen but not to the endogenous 
hormone estrogen (Figure 1c). The constructs differed with 
respect to five features: 1) the position of the ERT2 with re-
spect to the Cas9 (amino or carboxy terminal ERT2 fusion 
proteins, or ERT2 embed in an insertion point inside the 
Cas9, as Savage et al. 2016 showed was effective for a cata-
lytically dead dCas9), 2) the number of ERT2 copies in-
serted, 3) the presence/ absence of a SV40 nuclear localiza-
tion signal (NLS), 4) the incorporation of a 3-amino-acid 
               
Figure 5. a) Irreversible expression of mCherry on T-REx-293 -TO- mCherry cells co-transfected with a 4-Hydroxytamoxifen in-
ducible Cas9 (upper picture). ERT2 was changed by a different nuclear hormone receptor, the hPR LBD resulting likewise, in 
mCherry appearance because of the TetR disruption (lower picture). 13 days after transfection (11 days after 4-OHT or mifepristone 
removal) are required for the complete reporter expression with both inducible Cas9. b) Flow cytometry analysis showing the 
percentage of mCherry positive T-REx-293 cells after co-transfection with the 4-Hydroxytamoxifen and the mifepristone Cas9 with 
or without drug addition.   
linker sequence (LEP) and 5) a myristoylation signal. The 
idea behind using a myristoylation signal was to promote 
the binding of ERT2 to the membrane until it is activated 
by 4-Hydroxytamoxifen, when it should dimerize and be 
imported into the nucleus along with the Cas9 (18). 
 
Our criteria for having made a successful drug-inducible 
Cas9 effector were that it should express low basal activity 
in the absence of drug and robust activation of the effector 
in the presence of the drug. Three of these constructs met 
these two criteria (Figure 4a):  1) ‘ECES’ - Cas9 flanked by 2 
copies of ERT2, one on the amino terminal and the other 
one on the carboxy terminal, 2) ‘ECEC’, being the same as 
ECES except that it had a nuclear localization signal be-
tween the carboxy-terminal of Cas9 and the ERT2, and 3) 
‘CEC’, the construct with the ERT2 embedded within the 
Cas9 sequence (at amino acid 231). The induction of 
mCherry reporter expression by these constructs, in the 
presence or absence of 1 µM 4-Hydroxytamoxifen, is shown 
quantitatively in Figure 4b and qualitatively in Figure 4c. 
Of the three constructs, ‘ECES” showed the maximum ac-
tivation but also had the highest basal activity. ECE, the 
construct that had ERT2 inside the Cas9 sequence, showed 
  
 
Figure 6. Cas9 and Cpf1 three dimensional structures (PDB 4008 and PDB 5B43 sequences visualized with Geneious 3D structure 
viewer). The Insertion points for the ligand binding domains of the hormone receptors ERT2 and hPR are the spaces located 
between the amino acids indicated in cyan and magenta 
 
the highest ratio of activation over basal activity (1:49). For 
that reason, we kept ECE as our best 4-Hydroxytamoxifen 
-inducible Cas9 fusion protein. 
 
Substitution of the 4-Hydroxytamoxifen-sensitive 
ligand binding domain with a mifepristone-sensitive 
one 
To further evaluate the capacity of the ECE 4-Hydroxy-
tamoxifen-inducible Cas9 construct to be adapted for con-
trol by alternative drugs, we replaced the ERT2 sequence 
with that of a different nuclear hormone receptor. We used 
the human progesterone ligand binding domain hPR-LBD, 
which binds to the synthetic steroid, mifepristone. The re-
sulting fusion protein system was able to disrupt the TetR 
in response to mifepristone in a manner very similar to the 
ECE 4-Hydroxytamoxifen-regulated construct (Figure 5). 
Furthermore, the basal activities for both the 4-Hydroxy-
tamoxifen-controlled and the mifepristone-controlled 
Cas9 were less than 1% of that of wild-cas9. (Suppl. Fig-
ure1). 
 
Adding drug control to the alternative CRISPR ef-
fector, Cpf1  
The CRISPR effector Cpf1 is an RNA-guided nuclease 
broadly similar to Cas9, but with some properties that 
make it more suitable for editing AT-rich regions and for 
generating cuts with overhangs. We therefore wondered 
whether our techniques for making Cas9 drug-controlled 
could be applied to Cpf1. The insertion site for ERT2 in our 
ECE Cas9 construct was suggested from the work of Savage 
et al. (2016), who identified insertion sites within Cas9 that 
can accept synthetic functional domains by creating and 
screening an unbiased Cas9 insertion library using ran-
domized transposition. When they mapped the crystal 
structure of the Cas9 they realised that ‘hotspots’ of useful 
sites were often located in flexible loops and the ends of 
helices. (19) This provided a good guide for the engineering 
of Cpf1 but Patel et al. (2016) showed that there is very poor 
sequence alignment between individual domains of Cas9 
their functional counterparts in Cpf1. Use of the same site 
to confer drug control on Cpf1 could not therefore be ex-
pected to work. In view of this, an analysis of the three-
dimensional structure of both Cas9 and Cpf1 was done to 
predict a possible insertion point for the CRISPR on the 
Cpf1.  We applied the general principles identified by Sav-
age et al. (2016) and sought a location within the 3D struc-
ture of Cpf1 that would allow extra amino acids to be added 
without any conformational interaction with the rest of the 
Cas9 structure, the gRNA or the DNA. Cpf1 has a bi-lobed 
scaffold with a ‘crab claw’ shape (Figure 6). (20), so we 
chose the flexible loop around the joint at the top of the 
“crab claw”, a protrusion of Cpf1 which comprises the AA 
584 (Glu) and 585 (Lys) represented on cyan and magenta 
in Figure 6, as a location most likely to be suitable. We be-
lieve this to be the first time that an active Cpf1 has been 
engineered with ligand-binding domains of hormone re-
ceptors. 
 
We created two fusion proteins, one with ERT2 in this 
location within Cpf1, and the other with hPR-LBD there. 
We then tested the 4-Hydroxytamoxifen- and mifepris-
tone-inducibility of Cpf1 and we compared it to the drug-
controlled Cas9. The number of mCherry positive cells af-
ter the addition or not of 4-Hydroxytamoxifen or mifepris-
tone was quantified by FACS sorting and compared with 
  
 
Figure 7. a) Schematic representation of the tamoxifen- and mifepristone- inducible versions of CRISPR effectors, Cas9 and Cpf1. 
b) mCherry quantification by flow cytometry after the addition or not of 4-Hydroxytamoxifen (to the ERT2 controlled CRISPR) or 
mifepristone (to the hPR controlled CRISPR).
the number of cells expressing mCherry after TetR disrup-
tion with the wild type Cas9 or Cpf1 (Figure 7: as negative 
controls we used cells that expressed the TetR but that 
were not transfected with the CRISPR systems). In the ex-
perimental groups, both Cpf1 fusion proteins were able to 
efficiently disrupt the TetR, and they showed lower basal 
activity and higher activity than both inducible Cas9 sys-
tems. Mutations of the TetR were confirmed using the T7 
assay (Supplementary Figure 2). 
 
To summarize, our objective was to add extra layers of 
control to the CRISPR/Cas9 and CRISPR/Cpf1 gene-editing 
systems to allow them to be activated only in the presence 
of an exogenously applied drug. Our results demonstrate 
that we have produced 4-Hydroxytamoxifen- and mifepris-
tone-inducible versions of both Cas9 and Cpf1 with a very 
low basal activity but with strong activity following activa-
tion.  
We expect that over the next years we will experience an 
increase on the strategies to develop efficient inducible 
systems for mammalian gene expression in parallel with 
further crystallographic studies of well-studied and new 
proteins. In-depth studies of the three-dimensional struc-
ture of proteins may lead to improvements in the field of 
protein engineering by creating new fusion proteins capa-
ble of transcriptional activation or repression, which in 
turn can be used to develop new synthetic biology tools for 
mammalian gene expression systems. 
 
CONCLUSIONS: 
For this paper, we engineered two different drug-sensi-
tive domains into Cas9 and Cpf1. In principle, the drug-
controllability could be customized further by replacing 
the ligand binding domain of the fusion protein. Also, the 
targeted genes can be customized by changing the gRNAs. 
Among the advantages of the system, we can highlight the 
fact that the target proteins were modified to be responsive 
to an already existing drug, that it showed low basal activ-
ity and high induction capacity, that the system is compat-
ible with mammalian cells, and features modularity to al-
low fine-tuning the system. All these features are highly 
desirable for control of mammalian gene expression.  
 
MATERIAL AND METHODS 
Plasmid construction:  
pTrex-mCherry: The mCherry gene was cloned from 
pCherryPicker2 (Clontech) and PCR amplified with pri-
mers containing attachment (att) sites for Gateway® re-
combination according to manufacturer’s instructions and 
recombined by BP reaction in vector pDONR-221 (see sup-
plementary table 1 for primer sequences). The mCherry 
was subsequently inserted from the pENTR vector into pT-
REx-DEST30 (Thermo Fisher Scientific), by LR reaction ac-
cording to manufacturer’s (Thermo Fisher Scientific) in-
structions. 
Fusion proteins: pCas9_GFP (Plasmid #44719 addgene) 
was used to make all the Cas9-containing plasmids. Briefly, 
gblocks from IDT were created for the modified ligand 
binding domain of the mutated estrogen receptor (ERT2), 
the ligand binding domain of the human progesterone re-
ceptor, a nuclear localization signal, a 3 aa peptide linker 
and a myristoylation signal (all sequences in supplemen-
tary Table 1). Using Gibson assembly  to assemble the frag-
ments resulted in the following contructs: ERT2-Cas9; 
Cas9-ERT2-NLS; Cas9-ERT2; Cas9-ERT2-NLS-LEP; Cas9-
ERT2-LEP; ERT2-Cas9-ERT2-LEP; ERT2-Cas9-ERT2-NLS-
LEP, ERT2-Cas9-ERT2; ERT2-Cas9-ERT2-NLS ; Myr-Cas9-
ERT2-NLS-LEP ; Myr-Cas9-ERT2-LEP ; Myr-Cas9 ; Cas9-
ERT2-Cas9 ; Myr-Cas9-ERT2-Cas9 ; Cas9-hPR-Cas9 ; Myr-
Cas9-hPR-Cas9, where ‘NLS’ is a SV40  nuclear localisation 
sequence, ‘Myr’ is a myristoylation site and ‘LEP’ is the 3AA 
linker L= Leucine, E=Glutamic acid, P=Proline  
 pY010 (pcDNA3.1-hAsCpf1) (Plasmid #69982 addgene) 
was used along with gblocks to make all the Cpf1-contain-
ing plasmids.  Constructs: Cpf1-ERT2, Cpf1-ERT2-LEP; 
Cpf1-ERT2-Cpf1; Cpf1-hPR-cpf1.  
For both, the Cas9 and the Cpf1, all the fragments were 
cloned by Gibson assembly Hifi assembly master mix 
(NEB, REF: E2621S) and transformed in NEB 5 alpha com-
petent E. coli cells (NEB REF: C2987H). Plasmids were pu-
rified using the maxi prep kit from Qiagen (Ref: 12163). 
gRNA-carrying plasmids: For designing gRNAs that 
would target the TetR gene, the genomic sites of the form 
5’-NGG-3’ (for the cas9) and 5'-TTTN-3' (for the Cpf1) in our 
intended target site, the TetR, that were more likely to have 
high on target effects and low off target activity were cho-
sen with the CRISRP design tool of Benchling 
(https://benchling.com/). Following the recommenda-
tions of the gRNA Synthesis Protocol (21), a 455 bp or 399 
bp fragment for the Cas9 and Cpf1 respectively bearing the 
U6 promoter + target sequence + guide RNA scaffold + ter-
mination signal were synthesized as a gBlock from IDT and 
cloned with the Zero blunt cloning kit (Thermo Fisher Sci-
entific ref: K270020) into the empty backbone vector pCR-
Blunt II-TOPO from the kit. One Shot™ TOP10 Chemically 
Competent E. coli cells (Thermo Fisher Scientific ref: 
C404003) were used for transformation of the plasmids 
and maxi prep kits (Qiagen ref: 12163) used for purification. 
All the constructs were stored at -20 °C until transfection 
on mammalian cells.  
 
Mammalian cell culture and transfection 
Human Embryonic kidney cells (HEK-293 cells) that sta-
bly express the tetracycline repressor for the T-RExTM sys-
tem (T-REx™-293 Cell Line, Thermo Fisher Scientific ref: 
R71007) were maintained in a humidified incubator at 37°C 
and 5% CO2, in complete medium. This consisted of Dul-
becco’s minimum essential medium (DMEM, Gibco 41966) 
supplemented with 10% FBS (Biosera ref: FB-1090). 24 
hours prior to transfection, T-REx-293 cells were harvested 
by trypsinization and seeded at a density of 80,000 cells in 
500µl of complete medium per well on 24 well plates. Cells 
were transfected using 1µl lipofectamine 3000 (Invitrogen 
ref: L3000008) and the pTrex-mCherry plasmid (800 ng) 
and kept in selection medium. This consisted of complete 
medium + 800 µg/ml G418 (Thermo Fisher Scientific 
11811023) + 5 µg/ml blasticidin (Thermo Fisher Scientific 
R21001. They were maintained under this selection for 2 
weeks and clones were isolated using cloning rings. Each 
resulting clone was tested with 1 µg/ml tetracycline to ver-
ify that mCherry expression was under tetracycline control 
and was afterwards transfected with wild-type Cas9/Cpf1, 
or our engineered drug-inducible Cas9/Cpf1, and the cor-
responding gRNA.  After 24 hours, the medium was re-
placed by fresh selection medium, with or without the in-
ducing drugs (1 µM 4-Hydroxytamoxifen or 10 nM mifepris-
tone).  
 
mCherry imaging/ fluorescence microscopy 
After transfection and treatment, cells were passaged 
twice a week and maintained for 2 weeks (without addition 
of inducing drugs) before image acquisition. Images were 
acquired using a Zeiss Axio Observer D1 inverted micro-
scope with an AxioCam MRm camera and 10x objective.  
 
Flow Cytometric analysis 
After image acquisition, mCherry expression was also 
detected by flow cytometry. Cells were washed with PBS 
(Phosphate-buffered saline Sigma ref: P4417) , dissociated 
with trypsin- EDTA ( sigma ref: T4174) , re-suspended in 
PBS with 0.1% BSA at a density of 15x106 cells/ml and fil-
tered using BD blue capped filter tubes (BD 352235) in or-
der to obtain single-cell suspensions, which were applied 
immediately to a BD LSRFortessa™ Cell Analyzer and ana-
lysed using the BD Biosciences FACSDiva Software. 
 
T7 assay 
Genomic DNA was isolated from the T-REx-293 cells us-
ing a DNA extraction kit protocol (DNeasy Blood & Tissue 
Kit Qiagen ref: 69504) according to the manufacturer's in-
structions. After that, the target region was amplified by 
PCR with Q5® Hot Start High-Fidelity 2X Master Mix (NEB 
ref: M0494S). All PCR reactions used the same conditions: 
35 cycles [98°C, 30 s; (98°C, 5 s; 58°C, 10 s; 72°C 20 s); 72°C, 
2 min; 4°C hold]. After amplification, PCR products were 
analysed by 1% agarose gel electrophoresis and purified us-
ing the QIAquick PCR Purification Kit (Qiagen ref: 28104). 
 
To generate heteroduplex DNA, the following conditions 
were used: 95°C for 5 min, 95°C to 85°C cooling (at a rate 
of -2°C/s), 85°C to 25°C cooling (at a rate of -0.1°C/s), hold 
at 4°C. Following denaturation/renaturation of the ge-
nomic PCR samples, 1 μl of T7E1 (New England BioLabs.) 
was added to the samples and digestion reactions were in-
cubated for 1 h at 37°C. After digestion 1 μl of 0.25 M EDTA 
was used to stop the enzymatic reaction. Undigested PCR 
samples (as a control) and T7E-digested PCR products 
were electrophoresed on a 2% agarose gel. 
 
Statistical analysis 
The means ± SEM of multiple independent measure-
ments were calculated. Normality was tested through the 
Anderson-Darling Normality Test. Homoscedasticity with 
Bartlett's Test. A One-way ANOVA with Tukey Pairwise 
Comparisons was used to determine whether there were 
differences between some groups. A two-tailed Student's t-
test was used to test the null hypothesis that there was no 
difference between groups. 
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